The Board of directors at its meeting held today i.e. January 21, 2026 has approved the conversion of 7,75,000 share warrants in to Equity.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Venmax Drugs and Pharmaceuticals approved the conversion of 7,75,000 convertible warrants into equity shares on January 21, 2026. The shares were allotted at Rs. 20 each (face value Rs. 10 + premium of Rs. 10) to three non-promoter warrant holders — Sankalp Sunil Wakkar (1,25,000), I2 Pro Services Pvt Ltd (1,00,000), and Manish Grover (5,50,000). The company received Rs. 1.16 crore as the balance 75% exercise price. Following this allotment, the paid-up equity capital rose to Rs. 8.78 crore, comprising 87,82,930 shares. Out of the original 1,00,25,000 warrants issued on March 20, 2025, about 64,81,000 warrants remain outstanding and may be converted later, signalling further potential dilution.
Existing shareholders face modest equity dilution as 7.75 lakh new shares are added, and another ~64.8 lakh warrants still pending conversion could dilute further. The fresh capital infusion is small (~Rs. 1.16 cr), so the direct financial impact on the stock is limited but worth tracking for future dilution events.